Wednesday August 1st, 2018
Increasing sales, improving balance sheet and declining stock price . . . another company that highlights the divergence between fundamentals and share price . . .
True the company is investing aggressively in R&D, and in the drug development space, this comes with significant risk, however with the price down nearly 50% from January, there is a chance that continued growth returns the share price to the mean for a return of 20-25%.
